Drug combination discovery depends on reliable synergy metrics; however, no consensus exists on the 11 appropriate synergy model to prioritize lead candidates. The fragmented state of the field confounds 12 analysis, reproducibility, and clinical translation of combinations. Here we present a mass-action based 13 efficacy masks synergistic interactions; (2) MSP frameworks are biased toward antagonism for drugs with 54 intermediate efficacy; and (3) DEP frameworks contain a Hill-slope dependent bias. The Hill-slope bias 55 results from satisfying the famous "sham" combination thought experiment, arguing against the merit of 56 sham-compliance as a measure of validity for synergy frameworks. Using two large combination datasets 57 [23, 24], MuSyC identifies real-world examples where the conflicting assumptions of previous drug synergy 58 frameworks misleads or impedes drug discovery efforts through these pervasive and predictable biases. We 59 therefore propose MuSyC as a consensus framework to interpret combination pharmacology and signify its 60 broad applicability to the study of drug mixtures.
This equation can be derived using the Law of Mass Action from a two state model of drug effect (left). Edge notation is equal to the ratio of states at equilibrium ( A1 U ). The Hill equation contains parameters measuring a drug's efficacy (E 0 − E 1 ), potency (C), and cooperativity (h). Each parameter corresponds to distinct geometric transformations of the dose-response curve (right). B) Two-drug model: MuSyC is derived from a four-state mass-action model of combination pharmacology (left) and results in a 2D Hill-like equation describing a dose-response surface (middle). Edge notation denotes the ratio of the connected corners for the boundary condition. For example, edge #3 annotation means A12 A1 → C1 α21d1 γ21h1 when d 2 → inf. Beyond the parameters of the single Hill equation, the 2D Hill equation has additional parameters (β, α, γ) corresponding to distinct transformations of the dose-response surface (right) (Video S1). These transformations directly measure the changes in a single drugs' efficacy, potency, and cooperativity due to the combination, and, therefore, are interpreted as synergistic efficacy (β), synergistic potency (α), and synergistic cooperativity (γ). There are two values for α and γ because each drug can independently modulate the potency and cooperativity of the other [8, 9] (edge 3 vs. edge 4 of the state transition model). In contrast, the single β parameter describes the percent increase in maximal effect due to both drugs (effect at A12). See Figure S1 for MuSyC extension to three drugs. Measured effect at (d 1 , d 2 ). C 1 ,C 2 The concentration of drug required to achieve 50% of the maximal effect (i.e., EC 50 ). h 1 ,h 2
Hill coefficients for dose response curves of drug 1 and 2 in isolation. E 0
The basal effect E d (d1 = d2 = 0). E 1 ,E 2 Maximal efficacy of drugs 1 and 2 in isolation. E 3 Maximal efficacy of the combination of drugs 1 and 2. β Percent increase (or decrease) in max effect with both drugs over the most efficacious single drug (β := min(E1,E2)−E3 E0−min(E1,E2) ). α 12 Fold change in the potency (C 2 ) of [d 2 ] induced by drug 1. α 21 Fold change in the potency (C 1 ) of [d 1 ] induced by drug 2. γ 12
Fold change in the cooperativity (h 2 ) of [d 2 ] induced by drug 1. γ 21 Fold change in the cooperativity (h 1 ) of [d 1 ] induced by drug 2.
Box 1 Deriving Hill Equation from Mass Action Kinetics Consider a reversible transition between an unaffected population (U ) and an affected population (A) governed by
where d is the concentration of the drug, h is the Hill slope, often called cooperativity, and r1 and r−1 are constants corresponding to the reaction rate ( Figure 1A ). Applying the Law of Mass Action, steady state ratios of U and A are determined to be dU dt = A · r−1 − U · r1d h ≡ 0
. This dose is commonly called the EC50 (herein denoted as C). Because 100% of the population is either unaffected or affected, we also have the condition U + A = 1. This leads to the 2-parameter 1D Hill equation
If the U and A differ by an observed effect (such as proliferation rate [26] ), the measured effect E at dose d will be a weighted average E = U · E0 + A · E1, where E0 and E1 are the the effects characteristic of the U and A, respectively. From this we find the final form of a 4-parameter Hill equation:
2D extension of the Hill equation for two drug systems Consider a system with 4 possible states, U , A1, A2, and A1,2 corresponding to populations that are unaffected, affected by drug 1 alone, affected by drug 2 alone, or affected by both drugs, respectively. The corresponding reactions between these states are:
Here, the α parameters quantify the modulation of one drug's EC50 (potency) due to the other drug. Similarly, the γ parameters measure the change of a drug's Hill slope (cooperativity) due to the other drug. As in the 1D case, finding the steady state of the system leads to the following system of equations dU dt = −U · r1d h 1 1 + r2d h 2 2 + A1 · r−1 + A2 · r−2 (5) dA1 dt = −A1 · r−1 + r γ 12 2 (α12d2) γ 12 h 2 + U · r1d h 1 1 + A1,2 · (r−2) γ 12 dA2 dt = −A2 · r γ 21 1 (α21d1) γ 21 h 1 + r−2 + U · r2d h 2 2 + A1,2 · (r−1) γ 21 dA1,2 dt = −A1,2 · r γ 21 −1 + r γ 12 −2 + A1 · r γ 12 2 (α12d2) γ 12 h 2 + A2 · r γ 21 1 (α21d1) γ 21 h 1 At equilibrium, the equations 5 must all be equal to zero; however, the system only defines a rank 3 matrix. Taking the first three equations from 5 with the constraint U + A1 + A2 + A1,2 = 1, we define
such that M · U A1 A2 A1,2 T = 0 0 0 1 T or, solving for the proportions of each state,
If we again consider distinct effects E0, E1, E2, and E3 distinguishing populations U , A1, A2, and A1,2, we find the equation for the dose response surface to be
As d1 ← ∞ the equation reduces to A) The Bliss null model, the base model for all MSP frameworks, emerges from MuSyC when E 0 = 1, α 12 = α 21 = γ 12 = γ 21 = 1, and E 3 = E 1 E 2 . B) The Loewe null model, the base model for all DEP frameworks, emerges from MuSyC when h 1 = h 2 = 1 and α 12 = α 21 = 0. The constraint on α indicates the drugs' activities are mutually exclusive (i.e., the double-drugged state A 1,2 does not exist). C) Network of relationships between synergy frameworks (nodes) grouped by their underlying principle (colors). The notation next to solid edges signifies conditions under which source model reduces to end model's null model. The dotted edge indicates MuSyC synergistic efficacy (β) is proportional to HSA as d 1 → ∞, d 2 → ∞. See Supplemental Section Derivation of the theoretical relationships between different synergy frameworks for complete annotation of the parameters defined in each method. Where possible, parameters from each framework were translated in terms of the dose-response parameters defined for MuSyC (Table 1) to facilitate comparison.
Conflating synergistic potency and efficacy masks synergistic interactions 120
To determine how conflation of distinct synergy types impacts the interpretation of drug-response data, 121 we generated synthetic dose-response surfaces using MuSyC (eq (8)) across a range of α and β values and 122 Table 2 : Comparison of traditional and modern frameworks for calculating synergy. *CI has 2 equations for synergy in the original derivation [3] , for the mutually exclusive and mutually non-exclusive case. The mutually exclusive case, which is equivalent to Loewe, has been widely adopted and is the model compared here. Figure 3A ,D,G and Video S2). In each case, many distinct sets of (α 12 , α 21 , β) are indistinguishable (e.g.
124
the black contour line on the spheres).
125 Figure 3A shows that near the boundary between synergism and antagonism, Loewe is insensitive to Figure S4 for an example surface). This reflects Loewe's assertion of 129 infinite potency antagonism (α 12 = α 21 = 0, Figure 2A ) in its null model. Therefore, combinations that 130 are antagonistically potent (α < 1) are all synergistic by Loewe in the absence of sufficient antagonistic 131 efficacy (values above black contour in Figure 3A ). Indeed, Loewe is frequently synergistic even in cases 132 of antagonistic potency and efficacy ( Figure 3B bottom distribution). As an example, the combination of 133 methotrexate (targets folate synthesis) and erlotinib (EGFR inhibitor) in UWB1289 (BRCA1-mutant ovarian 134 carcinoma) cells is antagonistically efficacious and potent by MuSyC, but synergistic by Loewe ( Figure 3C ).
135
Bliss synergy is classically thought to calculate synergistic potency. This is because assays where Bliss 136 is appropriate (E 0 = 1 and E1 = E2 = E3 = 0) by definition have no synergistic efficacy. However, even 137 in these cases, Bliss still conflates α 12 and α 21 such that asymmetric potency synergy is obfuscated ( Figure   138 3D, black contour line through β = 0 plane). In the anti-malarial dataset from Mott et. al.
[24], Bliss 139 is consistently synergistic when log(α 12 , α 21 ) > 0, and antagonistic if log(α 12 , α 21 ) < 0; however, when 140 log(α 12 ) < 0 < log(α 21 ), Bliss will strictly classify a combination as either synergistic or antagonistic ( Figure   141 3E bottom distribution) despite the asymmetric interactions. As an example, Bliss conceals that halofantrine 142 (inhibits polymerization of heme molecules) reduces the potency of mefloquine (targets phospholipids) against 143 the multi-drug resistant malaria strain HB3 ( Figure 3F ).
144
In contrast to Bliss, HSA is commonly thought to quantify synergistic efficacy. However, for antago- . For all combinations: E 0 = 1, E 1 = E 2 = 0, h 1 = h 2 = 1, d 1 = d 2 = C 1 = C 2 , γ 12 = γ 21 = 1. The solid line marks the boundary between Loewe synergy and antagonism. Along this contour, which includes many different sets of (α 12 , α 21 , and β), Loewe is equivalent (-log(Loewe)= 0). Gray planes correspond to β = 0, log(α 12 ) = 0, and log(α 21 ) = 0. in effect over the single agents, even when each drug is administered at saturating concentrations ( Figure   161 4A middle panel). In contrast, if combining drugs with high or low efficacy, Bliss expects a more modest 162 increase ( Figure 4A left and right panels).
163
Based on this expectation that E 3 = E 1 ·E 2 (Figure 2A ), MuSyC predicts Bliss would be biased toward an-164 tagonism in combinations of moderately efficacious drugs ( Figure 4B yellow shading around E 1 = E 2 ≈ 0.5).
165
As expected, the median Bliss score in the anti-cancer dataset is biased toward antagonism for moderately assumption can lead to poor fits of percent effect data for moderately efficacious drugs, and thus invalid 175 synergy scores (see Figure S5 ). and their combination is synergistic by Loewe. However, using MuSyC, we see this combination is both 197 antagonistically efficacious and antagonistically potent ( Figure 5D ). Box 2 Sham compliance of MuSyC, and the mass action biochemistry of a sham experiment To simulate a sham experiment using MuSyC, there is no state A 1,2 ( Figure 1B) , which requires α 12 = α 21 = 0. Further, because drugs 1 and 2 are the same, h 1 = h 2 = h, C 1 = C 2 = C, and E 1 = E 2 . Thus, the 2D Hill equation (eq. (8)) reduces to
In comparison, the true dose-response surface of a sham experiment can be analytically determined from the 1D Hill dose-response equation (eq. 3) as
True Sham
Equations 10 and 11 are only equivalent when h = 1. This makes sense, as the constraints on α and h are the conditions required for MuSyC to satisfy the DEP ( Figure 2B) . To see what happens when h = 1, consider, for instance, a molecule with three binding sites targeted by a small molecule inhibitor (h = 3). For clarity, we assert E 0 = 1 and E 1 = 0, though the findings are valid more generally. The MuSyC sham surface follows
MuSyC Sham
In contrast, the true sham surface is
True Sham (12) The two additional cross-terms in the true sham equation (3
C 3 ) describe the six possible mixtures of drugs 1 and 2 that, together, fill all binding sites ( Figure 5A , blue, green, and magenta paths show three possible mixtures). In a sham experiment, because drugs 1 and 2 are the same, the diagonal states (black and cyan circles) in Figure 5A are all equivalent, and fully inhibited. Conversely, in non-sham combinations, drugs rarely target the same binding sites, or even the same molecule. Even when two drugs are mutually exclusive inhibitors of the same molecule and have the same number of binding sites, the cross-terms describe non-equivalent, not fully inhibited states ( Figure 5B ). A commonly applied and physiologically supported approximation is that only fully bound molecules become (in)active (see reaction schemes 5-7 in [28] ). Partially bound cross-terms are therefore reasonably modeled as unaffected, and the absence of these cross-terms from equation (10) is justified for real (non-sham) combinations (see Discussion). Further, when the two drugs do not target the same molecule or are mutually exclusive or have the same number of binding sites, by far the preponderance of real combinations, the diagonal states are ill defined yet remain embedded in the sham equation. Figure 5 : Enforcing sham compliance results in Hill-slope dependent bias in DEP frameworks. A) An illustration of the unique biochemistry of the sham experiment. The red circle represents an undrugged molecule with 3 binding sites. In a sham experiment, a drug is treated as though it were two separate drugs (green and blue polygons). Mixed states in which the binding sites are bound by both green and blue drugs (black circles) are equivalent to fully drugged states (cyan circles). We highlight three paths (green, blue, magenta arrows) that can be followed to reach a mixed-drugged state. These three paths correspond to the coefficient of 3 d1d 2 2 C 3 in equation (12) in Box 2. B) In a combination of mutually exclusive drugs (triangle and polygon), targeting the same molecule, and with the same number of binding sites, the mixed states (black circles) are not equivalent to fully drugged (cyan circles) accounting for the discrepancy between MuSyC and the sham experiment (Box 2). C) Loewe synergy is biased by Hill slope in the anti-cancer drug screen. The orange shaded regions show moving window percentiles (window width is 0.1) of Loewe (10th through 90th percentiles, in steps of 10). The top panel shows how many data points are present in the window. The blue curve in the middle plot shows the median MuSyC-predicted bias as a function of geometric mean of the Hill slopes (see Methods). Subtracting the MuSyC-estimated bias (calculated for each data point) from Loewe yields the bottom plot. C) The antagonistically efficacious and potent combination of mk-4827 and doxorubicin is misidentified as synergistic by Loewe, because both drugs in isolation have Hill slopes h < 1.
Discussion
underlying assumptions, limitations, and biases of commonly applied synergy methods. We have shown 256 how MuSyC unifies the DEP and MSP thus providing a consensus framework for the study of combination 257 pharmacology. These findings provide much needed clarity to the field and should promote the reproducibility 258 of drug synergy studies across drug combination discovery efforts. Such a rigorous approach to the discovery 259 and application of drug combinations will open the door to the discovery of new and previously discarded 260 avenues for therapeutic mixtures.
261

Methods
262
We note the analyses conducted were not necessarily the same as those used in the original paper. Indeed 263 the limitations of the current frameworks forced customized analysis for each publication highlighting the 264 need for a consensus framework. Here we describe fitting protocol for drug metrics where the metric of 265 drug effect decreases as dose increases (E 0 > E 3 ) (e.g., anti-proliferative drugs); however, the framework is 266 equally valid if increasing the drug corresponds to increases the effect (E 0 < E 3 ) (e.g., percent effect) 267 Fitting 2D Hill equation 268 The following packages were used for fitting, data analysis, [37] . Fitting was done using a custom library written in Python2. Previously, we found it necessary to use a Metropolis Hastings Monte Carlo (MCMC) seeded with a particle swarm optimization (PSO) to fit the 2D Hill equation [21] . This was prompted by the inconsistent performance of standard non-linear least squares (NLLS) regression. In particular, we observed instances of calculated uncertainties in NLLS which were several orders of magnitude greater than the parameter value. This, we have discovered, is because the multi-collinearity between the Hill slope and the EC50 (C) inherent in the structure of the Hill equation-collinearities which are amplified when extending the Hill equation to 2D. The correlation between variable h and C is easiest to observe in a linearized 1D Hill equation (eq 13).
In eq. 13, the intercept of the line (h * log(C)) depends on the slope of the line (h). This correlation is problematic when trying to estimate the parameter uncertainty (σ) from NLLS regression because σ is estimated as the square root of the inverse Hessian, approximated to be J T J (where J is the Jacobian at the solution). J of the 4 parameter Hill equation is
When the Hill slope is large (e.g., h>5), the second two terms of the J cause the inverse of the Hessian 
272
For the fitting the 2D Hill equation in this study, we adopted a Monte Carlo sampling approach to calcu-273 late the fit parameter uncertainty. This is significantly faster than our previous method (PSO+MCMC)
274
[21] while maintaining reasonable calculations of the parameter uncertainties accounting for the multi- for (E 0 , E 1 , E 2 , C 1 , C 2 , h1, h2 is particularly salient when the dose-range is insufficient to observe the lower plateau of the dose-response.
294
Only combinations for which R 2 > 0.7 and the fitted EC50s of both drugs was less than maximum tested 295 dose for each (C 1 < max(d1),C 2 < max(d2)) were included for subsequent analysis. The anti-malarial drug combination data was downloaded from https://tripod.nih.gov/matrix-client/ from 304 the Malaria Matrix project. Blocks downloaded for analysis were: [1601, 1602, 1603, 1701, 1702, 1703, 1761, 1764] .
305
Only blocks with a mqcConfidence of greater than 0.9 were included. The drug effect was calculated as de-306 scribed in [24] . Effects less than -20% and greater than 120% were removed. The minimum and maximum 307 bounds for [E 0 , E 1 , E 2 , E 3 ] during 2D Hill equation fits were [90.,0.,0.,0.] and [110, 200, 200, 200] respectively.
308
Calculation of other synergy metrics 309 Bliss, Loewe, and HSA Bliss, Loewe, and HSA depend on the concentration of drugs so a combination can be synergistic at one dose, but antagonistic at another dose. Several methods have been proposed for extracting a single synergy metric per combination from these frameworks to enable comparisons between combinations [14, 23, 15, 16] . For our analysis, we calculate the synergy score at the combination of each drug's EC50 (Figure 3,5 ) or at the maximum tested concentration of each drug (Figure 4 ). The EC50 of each drug was calculated from the fits to the 2D Hill equation ( (8)) which we have observed to be more robust to noise when estimating the single drug pharmacologic profile. Assuming the notation for the 1D Hill equation and inverse Hill equation-which calculate effect (E given a dose (d) and a dose given an effect, respectively-are given by
where E x < E 0 , then equations for Bliss, Loewe,and HSA at the EC50 are:
where Ed(C 1 , C 2 ) is the measured effect of combining C 1 of d 1 and C 2 of d 2 . And equations for Bliss at the max of each drug is: Bliss = H1(max(d 1 )) * H2(max(d 2 )
These equations assume the metric of drug effect decreases as the dose increases. Because many single 310 agents did not reach 0% maximum efficacy, the EC50s (C 1 , C 2 ) were not necessarily 50% ( Figure S5 ). If 311 E(C 1 , C 2 ) < E 1 , E 2 then Loewe was undefined. We apply a − log 10 transformation the scale Loewe to match 312 the ranges Bliss and HSA are synergistic; therefore, f − log 10 (Loewe) > 0 the combination is synergistic and 313 if − log 10 (Loewe) < 0 the combination is antagonistic. Additionally, for Figure 3 and Figure 5 we had to 314 calculate the Hill-dependent bias in Loewe. For Figure 3 , we subtracted the Hill slope bias to only study 315 the impact of conflating synergistic potency and efficacy. To calculate the bias, Loewe was calculated as 316 in equation (19) where Hx inv was was evaluated at the MuSyC-predicted Ed(d1, d2) for the combination 317 retaining all the single drug parameters (E 0 , E 1 , E 2 , C 1 , C 2 , h1, h2) and assuming (α 12 = α 21 = 0). to calculate the synergy of this model, we defined the sum of residuals between the null surface and the 334 experimental data to the metric of synergy.
335
Combination Index (CI) Following the CI fitting algorithm in the CompuSyn software, we fit the median-effect equation, a 2parameter, log-linearized form of the Hill equation obtained by assuming E 0 = 1 and E 1 = 0 [3]. C and h were then obtained from the slope and y-intercept of the log-linearized data using the scipy.stats.linregress module in Python 2.7. While CI assumes the drug effect is scaled between (0,1), when this is not the case, a poor fit results ( Figure S5A ). All data points with percent viability greater than 1 were excluded from the CI fit because the median-effect equation becomes complex in those cases. For some drugs, this left too few points to fit a line, such that CI was undefined. In other cases, the fitted value for h was less than zero, a physically unrealistic result; therefore, those combinations were also considered undefined. After that, CI was calculated as
where f i (E) is obtained by solving the Hill equation for d, and is given by
As with Loewe, we apply a − log 10 transformation to scale CI synergy such that − log 10 (CI) > 0 the 336 combination is synergistic and if − log 10 (CI) < 0 the combination is antagonistic.
337
Videos 338 Video S1: Synergistic efficacy (β), synergistic potency (α), and synergistic cooperativity (γ) correspond to 339 orthogonal geometric transformations of the dose response surface.
340
Video S2: Calculations of Loewe, Bliss and HSA for different sets of (α 12 , α 21 , β) on a spherical manifold. Figure S1 : A) Extension of MuSyC to combinations of three drugs. Following the cubic geometry of Figure  1B , combinations of 3 drugs result in a cube. Numbered notation next to each edge corresponds to the ratio of the connected corners at equilibrium for the boundary conditions. For example, edge #10 annotation
For combinations of 4 drugs, the geometry is a tesseract. In general, MuSyC can describe combinations N -drug combinations by considering 2 N possible states with transitions defining the edges of an N -dimensional hypercube. Dose-response surfaces generalize to N -dimensional scalar functions. In the most general case, for N drugs there are 2 N − N − 1 distinct β parameters (one for each state characterized by the action of at least 2 drugs), and n · 2 n−1 − 1 distinct α and γ parameters (one for each edge, excluding edges connected to the undrugged state, which correspond only to single-drug potency and cooperativity). Thus, MuSyC can account for higher-order synergyies (e.g., synergy that emerges from a combination of three drugs, but is not evident in any pairwise combination of those drugs), however the rapid growth of the number of synergy parameters with N suggests that significant quantities of data, or confident knowledge of pairwise synergies, would be needed to measure such higherorder synergies. Figure S3 : A) Difference in the Akaike Information Criterion (AIC) values for MuSyC models including fitting synergistic cooperativity (γ 12 and γ 21 ) or fixing γ to 1 thereby reducing the parameter count by 2. Models which minimize AIC are preferred. In most cases the simpler model is preferred. The mean AIC γ − AIC noγ for anti-cancer and anti-malarial datasets was 8 and 3312, respectively. The percent of combinations for which the model including γ had a lower AIC value was 18% and 5%, respectively. A Figure S4 : A) The combination of L778123 (a dual farnesyl and geranylgeranyl transferase inhibitor) and temozolomide (DNA alkylating agent) in COLO320DM cell lines is synergistically efficacious but antagonistically potent, and is an example where Loewe misses antagonistically potent interactions. 
A B
MuSyC Figure S5 : A) Dose-response surface for combination erlotinib and abt-888 in SW837 cells. B) Dose response surface according to Effective Dose model, which enforces E 0 = 1 and E 1 = E 2 = 0. C) Dose-response surface for dasatinib and oxaliplatin in NCI-H520 cells. MuSyC matches the Bliss null surface when there is no potency synergy (α 12 = α 21 = 1), no cooperativity synergy (γ 12 = γ 21 = 1), and E 3 = E 1 · E 2 (Figure 2A) . To show this, let each drug in isolation have a 1D hill response
where U i reflects the portion of cells unaffected by drug i alone. For the 2D case, when α 12 = α 21 = 1 and γ 12 = γ 21 = 1, each edge in Figure 1B satisfies detailed balance and therefore the state occupancy is given by
the MuSyC mass action model gives
From this, it is easy to verify that U = U 1 · U 2 where U 1 = 1 − (A 1 + A 1,2 ) and U 2 = 1 − (A 2 + A 1,2 which 481 is equivalent to the Bliss Independence null model.
482
Furthermore, given
We define U i , A i , and E i = U i + A i E i to be the fraction of unaffected cells, fraction of affected cells, and observed effect for treatment due to the single drug i, as described by equation 24. The overline distinguishes affects attributable to each drug, such that A 1 includes cells affected either by drug 1 alone, or by both drug 1 and drug 2, while A 1 only includes cells affected by drug 1, but not drug 2 (i.e., A 1 = A 1 + A 1,2 ). Then
From 25, we know U = U 1 · U 2 , and A 1,2 = A 1 · A 2 , leading to
Similarly, it is simple to show A 1 = U 2 − U , and similarly for A 2
If E 3 = E 1 · E 2 , then this is equivalent to equation (26). Therefore, given α 12 = α 21 = 1, γ 12 = γ 21 = 1, 483 E 0 = 1, and E 3 = E 1 · E 2 , MuSyC predicts E 1 · E 2 = E. Thus, while Bliss was derived purely within 484 the scope of "percent affected", MuSyC shows that the Bliss model may be appropriately extended to any 485 measure of effect for which E 0 = 1 and effects are expected to be multiplicative. Nevertheless, for effects 486 which do not satisfy these criteria, the Bliss model cannot be reliably used, while MuSyC may still be used 487 for arbitrary effects. The DEP defines asserts an expectation that for a given effect E, achievable either by dose d 1 of Drug 490 1 alone, or dose d 2 of Drug 2 alone, there is a constant ratio R = d1 d2 such that using ∆d 2 less of Drug 2 491 can always be compensated for by using ∆d 1 = R∆d 2 more of Drug 1 to achieve the same effect [11] . This 492 definition leads to the linear isoboles characteristic of the Loewe null model.
493
Chou and Talalay showed that linear isoboles emerge when the two drugs are mutually exclusive [40] , meaning that the double-drugged state (A 1,2 in Figure 1B ) is unreachable. In MuSyC, this requires setting α 12 = α 21 = 0, which reduces the 2D Hill equation (eq. (8)) to
From this equation it is easy to see when h 1 = h 2 = 1, the conic section reduces to a line, resulting in the canonical linear isoboles of Loewe Additivity and the CI null models. Further from equation (27), we find the slope of isoble is equal to − C2 C1 as shown by: Zimmer et. al. [8] introduced the effective dose model as a parameterized extension of Bliss, and to our knowledge were the first to account the asymmetric potency synergy, which is also present in MuSyC. The effective dose model is constructed by fitting the dose response of each single drug to a two-parameter 1D Hill equation in which E 0 and E max are fixed at 1 and 0, respectively 
The parameter a 12 represents how drug 2 modifies the effective dose synergistically (a 12 < 0) or an-506 tagonistically (a 12 > 0) drug 1. Note that as a 12 → −
, d 1,ef f → +∞, and as a 12 → +∞, 507 d 1,ef f → 0, which defines the bounds over which a 12 is defined. The authors then fit the a parameters using 508 a surface model based on MSP [41] ( Figure S5 ). In contrast, MuSyC is able to fit dose response surfaces with arbitrary effect ranges. In contrast to the Effective Dose Model, ZIP, accounts for changes in both the Hill slope and the potency across the dose-response surface. In ZIP, these changes are integrated into a single number (δ), given by
ZIP is formulated for arbitrary E 0 and E max ; however, it assumes E max is the same for both drugs, as well 520 as the combination (E 1 = E 2 = E 3 ). To calculate δ, the ZIP method fixes the concentration of one drug, 521 then fits a Hill-equation dose response for the other drug. However, for combinations with efficacy synergy or 522 antagonism, slices of the dose-response surface can have non-Hill, and even non-monotonic shapes. In these 523 cases, ZIP parameter fits may not be meaningful. Because MuSyC accounts explicitly for efficacy synergy, 524 its surfaces are able to describe such complex drug combination surfaces where ZIP cannot.
525
Nevertheless, ZIP parameters µ and η are closely related to MuSyC parameters α and γ. In the absence of synergistic efficacy, slices of MuSyC dose-response surfaces are sigmoidal, though in general do not perfectly follow a Hill equation, and so the ZIP model is still not identical to MuSyC. However, at saturating 
concentrations of one or the other drug, MuSyC does reduce to the Hill equation. In these saturating cases, ZIP's δ can be related analytically to MuSyC's α and γ by
is an extension of the DEP to effects exceeding the weaker drug and consequently reduces 527 to Loewe under particular conditions (Figure 2 ). The authors propose three BRAID models with increasing 528 complexity, with eBRAID capable of describing the most general dose-interaction surfaces. We focus our 529 analysis on eBRAID, which assumes that each drug alone has a Hill-like response, and constructs an Hill-like 530 equation for the combination
where
The BRAID equation (eq. (32)) uses a dose parameter, which combines the doses of both individual drugs, 532 using a parameter κ and a parameter for the Hill slopes δ which acts as a multiplicative of the geometric mean 
non-monotonic responses, unlike ZIP. Additionally, because BRAID fits the whole combination surface using 536 a single parameter, it can be used to make unambiguous statements about whether the combination is 537 synergistic or antagonistic. Nevertheless, BRAID does not account for differences in synergy due to efficacy, 538 potency, and cooperativity, whereas we find many combinations that are synergistic with respect to one, 539 but antagonistic with respect to the other ( Figure 3C ). Though κ and δ are related to the potency and 540 cooperativity respectively, their biochemical interpretation is not straightforward. Highest single agent (HSA) [11] is a parsimonious model that defines synergy as the net difference between the combination response and the stronger single-drug response
This form assumes that drug decreases E, though it can also be defined for drugs that increase E. At high 
2D Hill PDE
The most recent framework is one by Schindler [10] which interpolates a null dose-response surface from 549 the single dose-response curves alone without any fit parameters. This was done by using PDE Hill equations 550 and then imposing boundary conditions as well as sham compliance. It is therefore an extension of Loewe 551 to effects greater than the least efficacious drug (Figure 2 , Table 2 ). The boundary conditions enforce the 2) ZIP was proposed as a framework that unifies Loewe Additivity (DEP) and Bliss Independence (MSP), 570 much like MuSyC. In support of this, they prove ZIP is sham-compliant; however, we identified an error in 571 their proof. Further, we generate in silico sham response data and show that ZIP fails the sham experiment.
572
For this reason, we place ZIP as an MSP method in Figure 2C , and not DEP. However, we have contended 573 that satisfying the sham experiment should not be a sought-after standard in drug combinations, so we do 574 not consider it a shortcoming of ZIP that it does not. Chou and Talalay report that the combination index for mutually exclusive drugs satisfies the sham 577 experiment, whereas for MuSyC, we find this is only true when h = 1 (eq (10)). Because MuSyC's underlying 578 model ( Figure 2B) is identical to what Chou and Talalay describe [40] when α 12 = α 21 = 0, we sought to 579 discover the source of this discrepancy.
580
Chou and Talalay's finding comes from "Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors" [40] . We found an error in the section Inhibition of the Higher-Order Kinetic Systems by Mutually Exclusive Inhibitors. Specifically, the authors correctly solve the n-drug case with h = 1 A n drugs U = In general it is not clear how this would be calculated if each drug has a different value h, as there exists only a single h in their formula. However, in the case of n mutually exclusive drugs following Hill kinetics (a model graphically represented for n = 2 in Figure 2B ), we can say at equilibrium dA j dt = U r j d
hj j − A j r −j = 0
From this we can solve for Aj U for each drug, arriving at the same equation 12 from Chou [40] . But applying the constraint that U + A = 1, where A = n j=1 A j , we instead find the correct form for the multi-drug case with arbitrary h is A U = n j=1 d j C j
hj When h j = h = 1 the discrepancy between these equations vanishes because it does not matter that they m 1←2 is the amount x 1 of drug 1 that is needed to achieve an effect halfway between y 2 and 1 (the 585 asymptotic value at infinite drug), where y 2 is the effect achieved by adding an amount x 2 of drug 2.
586
Specifically, when x 1 = m 1←2 , y 1←2 = 1+y2 2 .
587
Sham experiments satisfy Equation (11) demonstrating that m 1←2 = m 1 for the sham experiment in the ZIP model, contradicting their proof that 589 ZIP is sham-compliant.
590
To verify ZIP identifies synergy or antagonism for sham combinations, we generated a synthetic sham 591 dose response surface. Sham experiments can be generated exactly for any drug with a pre-defined dose-592 response by asserting the condition in Equation (11). We constructed a synthetic dataset describing a sham dose response surface for a drug with h = 2, sampled at 2.5 orders of magnitude above and below the EC50.
A 1,2
At equilibrium A 1,2 A 1 = r γ12 2 (α 12 d 2 ) γ12h2 r γ12 −2
When A 1 = A 1,2 this is the EC50 for drug 2 given saturating concentrations of drug 1 (C 2 ). This dose can be found by solving the above.
The boundary then reduces to a Hill equation of the form
following the derivation in box 1. 
